Hermetica Superfood Encyclopedia
The Short Answer
Alafia barteri leaf extracts contain a complex of 70 identified phytochemicals — prominently 2-pyrrolidinone (14.03%), cyclotetrasiloxane (12.56%), and linoleic acid derivatives — that collectively exert antioxidant, anti-inflammatory, and antiplasmodial activities. In the most detailed preclinical study available, oral administration of 400 mg/kg aqueous leaf extract for 42 days produced a statistically significant reduction in blood glucose (p<0.05) in alloxan-induced diabetic rats alongside preserved pancreatic islet cytoarchitecture, though no human clinical trials have yet replicated or validated these findings.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary KeywordAlafia barteri benefits
Barteri Alafia — botanical close-up
Health Benefits
**Antiplasmodial Activity**
Aqueous leaf extracts demonstrate potent activity against Plasmodium species in preclinical models, supporting the plant's longstanding role in West African traditional antimalarial practice; the specific flavonoid and alkaloid fractions are presumed contributors though not yet isolated.
**Antidiabetic Effects**
Administration of aqueous leaf extract significantly reduced blood glucose levels in alloxan-induced diabetic Wistar rats (p<0.05) over a 6-week period, with histological evidence showing regeneration and preservation of pancreatic islet architecture.
**Anti-inflammatory Properties**
Both ethanol leaf and root extracts reduced carrageenan-induced paw edema in rodent models, indicating inhibition of prostaglandin-mediated inflammatory cascades; secondary metabolites such as phenolics and terpenoids are believed to contribute.
**Antimicrobial Action**
Leaf extracts exhibited broad-spectrum antibacterial and antifungal activity in vitro, suggesting membrane-disrupting or enzyme-inhibiting properties attributable to its fatty acid and pyrrolidinone constituents.
**Antioxidant Capacity**: The phytochemical profile
including linoleic acid (9,12-octadecanoic acid, 8.12%) and n-hexadecanoic acid (7.97%) — confers radical-scavenging properties that may underpin the plant's anti-inflammatory and cytoprotective effects.
**Anthelmintic Activity**
Bioactive compounds isolated from Alafia barteri have demonstrated vermicidal properties against parasitic helminths in laboratory assays, consistent with its traditional use in managing intestinal parasitic infections.
**Nutritional Contribution**
The leaves represent a source of dietary minerals and macronutrients accessible to rural West African communities, though comprehensive proximate analyses with quantified concentrations remain limited in the published literature.
Origin & History
Natural habitat
Alafia barteri is a woody liana native to the tropical rainforest belt of West and Central Africa, with distribution spanning Guinea-Bissau, Nigeria, Cameroon, and the Congo Basin. It thrives in humid, lowland tropical forest environments and forest margins, where it climbs over surrounding vegetation using its twining stems. The plant is harvested from wild populations for traditional medicinal use; no formal commercial cultivation or agronomic standardization has been documented.
“Alafia barteri has been integral to traditional healing systems across Nigeria, Cameroon, and neighboring West and Central African nations for generations, where herbalists deploy it as a remedy for malaria-related fever, inflammatory conditions, toothache, and ocular infections. Its use is embedded within indigenous pharmacopeias that recognize it by local vernacular names across Yoruba, Igbo, and other linguistic communities, reflecting deep ethnomedical knowledge of its therapeutic potential. The plant belongs to the Apocynaceae family — a lineage historically prolific in pharmacologically active alkaloids, many of which have yielded mainstream pharmaceuticals such as vinblastine and reserpine — lending ethnobotanical credibility to Alafia barteri's traditional reputation. Formal scientific investigation of the plant began in earnest in the early 21st century, driven partly by global interest in African ethnomedicinal plants as sources of novel antimalarial and antidiabetic lead compounds.”Traditional Medicine
Scientific Research
The scientific evidence base for Alafia barteri consists entirely of preclinical animal studies and in vitro phytochemical analyses; no peer-reviewed human clinical trials have been published as of the available literature. The most rigorous study employed alloxan-induced diabetic Wistar rats (specific n not reported in available summaries) receiving 400 mg/kg oral aqueous leaf extract daily for 42 days, reporting statistically significant blood glucose reduction (p<0.05) and preserved pancreatic and gastric histology. GC-MS phytochemical profiling of ethanol leaf extract identified 70 distinct compounds, providing a compositional foundation but not establishing dose-response or pharmacokinetic parameters in humans. The overall evidence level is low by clinical standards: no randomized controlled trials, no pharmacokinetic studies in humans, no defined bioavailability data, and no established standardization of extract potency exist.
Preparation & Dosage
Traditional preparation
**Traditional Leaf Decoction**
Leaves are boiled in water and the resulting decoction is consumed orally for fever, malaria, and inflammation; no standardized volume or concentration is established in the ethnobotanical literature.
**Traditional Root Decoction**
Root material is prepared similarly as a decoction and applied or consumed for toothache and eye infections in Nigerian and Cameroonian traditional practice.
**Aqueous Leaf Extract (Research Grade)**
400 mg/kg body weight administered orally in a rat model over 42 days; human equivalent dosing cannot be directly extrapolated without pharmacokinetic bridging studies
The only quantified dose in the literature is .
**Ethanol Leaf Extract (Phytochemical Research)**
Used in GC-MS analyses and in vitro antimicrobial and anti-inflammatory assays; not characterized for human supplemental use or standardized to any specific marker compound.
**No Commercially Standardized Supplement Form Exists**
Alafia barteri is not currently available as a standardized dietary supplement; all preparations are traditional or research-context only.
Nutritional Profile
Alafia barteri leaves have been identified as a potential dietary mineral and nutrient source for communities in its native range, though comprehensive proximate composition data with precise concentrations are not yet published in the accessible literature. The GC-MS-identified lipid constituents include n-hexadecanoic acid (palmitic acid, 7.97%) and 9,12-octadecanoic acid (linoleic acid, 8.12%), indicating a meaningful presence of essential and semi-essential fatty acids within the leaf extract. Secondary metabolites identified include 2-pyrrolidinone (14.03%) — a lactam compound with reported bioactivity — and cyclotetrasiloxane (12.56%), alongside a diverse array of minor phytochemicals contributing to antioxidant capacity. Bioavailability of these constituents from traditional aqueous decoctions versus ethanol extracts likely differs substantially, as lipid-soluble compounds would have limited solubility in water-based preparations, though no formal bioavailability studies have been conducted.
How It Works
Mechanism of Action
The antidiabetic mechanism of Alafia barteri appears to operate primarily through reduction of reactive oxygen species — specifically superoxide radicals generated under hyperglycemic conditions — which alleviates oxidative stress-induced apoptosis of pancreatic beta cells and supports islet cytoarchitectural regeneration. Anti-inflammatory activity is attributed to inhibition of the arachidonic acid cascade, likely through COX pathway modulation by phenolic and terpenoid secondary metabolites, as demonstrated in carrageenan paw edema models. The antiplasmodial effect is hypothesized to involve disruption of heme polymerization within the malaria parasite's digestive vacuole, a mechanism common to many Apocynaceae alkaloids, though the specific compound and confirmed molecular target in Alafia barteri have not been definitively identified. Antimicrobial activity likely involves disruption of microbial cell membrane integrity by fatty acid constituents such as n-hexadecanoic acid and linoleic acid derivatives, which intercalate into lipid bilayers and impair membrane function.
Clinical Evidence
All available clinical-grade evidence for Alafia barteri is derived from preclinical animal models rather than human trials, representing a significant gap in the translational evidence chain. The primary antidiabetic study used alloxan-induced diabetic Wistar rats dosed at 400 mg/kg/day orally for six weeks, measuring fasting blood glucose and histological endpoints; results showed significant glycemic reduction and pancreatic islet preservation relative to untreated diabetic controls. Anti-inflammatory and antiplasmodial endpoints have been assessed in rodent models using carrageenan paw edema and in vitro parasite culture assays respectively, yielding positive but non-quantified effect sizes in the available summaries. Confidence in translating these results to human therapeutic applications is very low, and regulatory or clinical use recommendations cannot responsibly be made from the current evidence base alone.
Safety & Interactions
Formal human safety data for Alafia barteri do not exist in the published literature; no clinical adverse event profiles, maximum tolerated doses, or toxicological studies in humans have been reported. In the primary animal study, administration of aqueous extract at 400 mg/kg was associated with progressive body weight gain throughout the 42-day treatment period, the clinical significance of which is uncertain and may reflect restoration of metabolic function in diabetic animals rather than a direct anabolic effect. No specific drug interaction data are available; however, given the documented antidiabetic and anti-inflammatory preclinical activities, theoretical interactions with antidiabetic medications (e.g., metformin, sulfonylureas) and anti-inflammatory or anticoagulant drugs warrant caution and prospective study. Pregnancy and lactation safety cannot be assessed from available data, and traditional use in these populations has not been systematically documented; avoidance during pregnancy and lactation is prudent until safety data are established.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Alafia barteriBarteri AlafiaApocynaceae liana West AfricaAfrican antimalarial liana
Frequently Asked Questions
What is Alafia barteri used for in traditional medicine?
In traditional West and Central African medicine, Alafia barteri is primarily used as an antimalarial and fever remedy, as well as for treating toothache, eye infections, and inflammatory conditions. Root and leaf decoctions are the predominant preparation forms, consumed orally or applied topically depending on the condition being treated.
Does Alafia barteri have scientific evidence for lowering blood sugar?
Preclinical evidence from an animal study demonstrated that 400 mg/kg of aqueous Alafia barteri leaf extract administered orally for 42 days produced a statistically significant reduction in blood glucose (p<0.05) in alloxan-induced diabetic Wistar rats, alongside preserved pancreatic islet integrity. However, no human clinical trials have been conducted, so the antidiabetic effect cannot yet be confirmed or safely recommended for human use.
What are the main bioactive compounds in Alafia barteri?
GC-MS analysis of the ethanol leaf extract identified 70 phytochemical components, with the most abundant being 2-pyrrolidinone (14.03%), cyclotetrasiloxane (12.56%), linoleic acid or 9,12-octadecanoic acid (8.12%), and n-hexadecanoic acid/palmitic acid (7.97%). The plant also contains secondary metabolites — including phenolics, alkaloids, and terpenoids — that are attributed to its antioxidant, anti-inflammatory, and antimicrobial activities, though the specific compound responsible for each therapeutic effect has not been definitively isolated.
Is Alafia barteri safe to use?
There are currently no published human safety studies, toxicology reports, or adverse event data for Alafia barteri, making it impossible to establish a confirmed safe dose or safety profile for human use. The animal study noted body weight gain during treatment, but no organ toxicity was specifically reported; nonetheless, individuals with diabetes, those taking medications, pregnant women, and breastfeeding mothers should avoid use until formal human safety data are available.
Where does Alafia barteri grow and how is it harvested?
Alafia barteri is native to the tropical rainforests of West and Central Africa, distributed across Guinea-Bissau, Nigeria, Cameroon, and the Congo Basin, where it grows as a woody climbing liana in humid lowland forest environments. The plant is currently harvested exclusively from wild populations for traditional medicinal use; there is no documented commercial cultivation, standardized harvesting protocol, or domesticated agronomic variety.
How does Alafia barteri compare to other traditional African antimalarial herbs?
Alafia barteri stands out among West African antimalarial plants due to its documented antiplasmodial activity against Plasmodium species in laboratory models, though direct comparative efficacy studies with other traditional remedies like Artemisia annua or Cryptolepis sanguinolenta remain limited. While all three have ethnobotanical antimalarial use, Alafia barteri's specific flavonoid and alkaloid profiles suggest a distinct phytochemical mechanism that has not yet been fully characterized. The choice between these plants traditionally depends on regional availability and specific disease presentation rather than established clinical superiority.
What form of Alafia barteri extract shows the strongest biological activity?
Aqueous leaf extracts of Alafia barteri demonstrate the most potent antiplasmodial and antidiabetic effects in preclinical research, which aligns with traditional preparation methods using water decoctions. This water-based extraction appears to effectively solubilize the active flavonoid and alkaloid compounds responsible for the plant's therapeutic properties. Dried leaf material used for aqueous extraction may preserve bioactivity better than fresh material, though direct bioavailability comparisons between aqueous extracts, standardized preparations, and whole leaf powders have not been systematically studied.
What populations would benefit most from Alafia barteri supplementation based on traditional use patterns?
Alafia barteri has traditionally been used primarily in West African communities for malaria prevention and management, as well as for glycemic control, suggesting potential benefit for individuals in malaria-endemic regions or those with elevated blood sugar concerns. However, clinical evidence supporting efficacy in specific populations (such as prediabetic individuals or those with partial antimalarial drug resistance) remains preliminary and derived mainly from preclinical models. Traditional use patterns indicate the herb was administered across adult age groups, but safety data in pregnant women, nursing mothers, and children remain inadequately studied for modern supplementation recommendations.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w barteri-alafia-alafia-barteri curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
